Henri Termeer joins Verastem board
This article was originally published in Scrip
Verastem, a biopharmaceutical company focused on discovering and developing cancer drugs by targeting cancer stem cells, has appointed Henri Termeer to its board of directors. Previously Mr Termeer was chairman, president and CEO of Genzyme for nearly 30 years.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.